Document Detail


Acute demyelinating optic neuritis: a review.
MedLine Citation:
PMID:  17981719     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute demyelinating optic neuritis (ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis (MS) is believed to be the most common etiology for ON. Nearly 50% of MS patients will develop ON, and in 15-20% of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22%, 52%, and 56% risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS.
Authors:
Steven David Brass; Robert Zivadinov; Rohit Bakshi
Related Documents :
16921179 - Grey matter damage predicts the evolution of primary progressive multiple sclerosis at ...
19463519 - Left ventricular conduction delays and relation to qrs configuration in patients with l...
20026709 - Analysis of the masseter muscle in patients with systemic sclerosis: a study by magneti...
20100229 - Relapsing neuromyelitis optica: demographic and clinical features in iranian patients.
17439889 - Advanced lightweight cooling-garment technology: functional improvements in thermosensi...
1029009 - Pattern visual evoked potentials in the diagnosis of multiple sclerosis and other disor...
11487459 - Antithrombotic secondary prevention after stroke.
2508019 - Rhinomanometric evaluation of two nasal steroid sprays in rhinitis.
19133919 - Serum eosinophil granule proteins predict asthma risk in allergic rhinitis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2008-01-01
Journal Detail:
Title:  Frontiers in bioscience : a journal and virtual library     Volume:  13     ISSN:  1093-4715     ISO Abbreviation:  Front. Biosci.     Publication Date:  2008  
Date Detail:
Created Date:  2007-11-05     Completed Date:  2007-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709506     Medline TA:  Front Biosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2376-90     Citation Subset:  IM    
Affiliation:
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Partners Multiple Sclerosis Center, Boston, MA, USA. sbrass@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Atrophy
Demyelinating Diseases / therapy
Diffusion
Female
Humans
Magnetic Resonance Imaging / methods
Magnetics
Optic Nerve / pathology*
Optic Neuritis / diagnosis*,  epidemiology,  pathology*
Placebos
Prognosis
Tomography, Optical Coherence / methods
Grant Support
ID/Acronym/Agency:
1R01NS055083-01/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Placebos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzy...
Next Document:  Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain.